MarginsXMarginsX
Home › Markets › Health Care › EBS

Emergent BioSolutions Inc. (EBS)

EBS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.81
+0.35% on the day
Market cap
$298.7M
Micro cap
Revenue · 2025
$742.9M
-28.8% on 2024
Net income · 2025
$52.6M
7.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/0001367644-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEBS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2006
SEC CIK0001367644
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$742.9M
Net income$52.6M
Operating income$100.1M
Net margin7.1%
Operating margin13.5%
Revenue growth-28.8%
Cash$205.4M
Total assets$1.3B
P/E (computed)5.7×
P/S (computed)0.4×

Warning signs

Cash runway
Cash-flow positive
$175.7M cash at September 30, 2026
Share count, 1 year
-2.1%
2025-10-22 to 2026-10-26 · -0.9% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$1.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$175.7M cash; operating cash flow $50.0M a quarter.Report 2026-09-30
Shares outstanding51,415,182 (2026-10-26); 52,519,964 a year earlier; 51,884,398 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Tysons, Virginia, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$110.0M-$32.7M$100.1M$175.7M$514.3M$649.1M10-Q 2026-11-03
Q2 2026
2026-06-30
$234.3M-$180.2M$56.1M$139.7M$589.7M$770.2M10-Q 2026-08-06
Q1 2026
2026-03-31
$156.1M$6.8M-$33.8M$160.3M$589.7M$676.8M10-Q 2026-05-01
Q4 2025
2025-12-31
$148.7M-$54.6M$77.7M$205.4M$589.7M$742.9M10-K 2026-02-27
Q3 2025
2025-09-30
$231.1M$51.2M-$2.3M$245.5M$693.1M$788.9M10-Q 2026-11-03
Q2 2025
2025-06-30
$140.9M-$12.0M$106.4M$267.3M$700.0M$851.6M10-Q 2026-08-06
Q1 2025
2025-03-31
$222.2M$68.0M-$11.2M$149.1M$700.0M$965.4M10-Q 2026-05-01
Q4 2024
2024-12-31
$194.7M-$31.3M-$79.9M$99.5M$700.0M$1.0B10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-08-07
Latest annual report10-K2026-02-27
Latest quarterly / interim
10-Q 9.30.26
10-Q2026-11-03
Latest current report
8-K PR 11.4.2026
8-K2026-11-04
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.5%
1 month-16.2%
3 months+29.0%
Year to date-53.2%
1 year-43.9%
From 52-week high-58.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALTAltimmune Inc.$1.56-5.17%$303.6M
EVMNEvommune Inc.$7.10-6.95%$293.6M
GALTGalectin Therapeutics Inc.$3.02-0.98%$305.2M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
PRLDPrelude Therapeutics Incorporated$3.41-1.16%$272.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier